Table 3 Baseline mean scores (SD) by treatment arm
EORTC-QLQ C30 | CR | TT |
|---|---|---|
(n=62) | (n=59) | |
physical functioning | 84,1 (18,7) | 83,2 (16,0) |
role functioning | 70,2 (27,4) | 66,4 (29,3) |
cognitive functioning | 86,0 (20,5) | 82,8 (22,3) |
emotional functioning | 78,8 (18,1) | 74,4 (20,0) |
social functioning | 80,6 (22,6) | 82,2 (19,8) |
fatigue | 29,7 (20,7) | 35,0 (24,9) |
nausea & vomiting | 7,5 (19,0) | 5,1 (15,2) |
pain | 24,7 (24,7) | 24,5 (24,4) |
global health status | 69,0 (21,7) | 67,2 (17,5) |
dyspnea | 11,3 (22,5) | 15,3 (26,5) |
insomnia | 26,9 (28,2) | 35,0 (29,3) |
loss of appetite | 12,9 (27,2) | 10,2 (18,8) |
obstipation | 12,4 (25,8) | 11,3 (18,2) |
diarrhea | 6,5 (16,9) | 4,0 (12,5) |
financial difficulty | 9,7 (24,4) | 13,0 (24,8) |
EORTC-QLQ BR23 | CR | TT |
(n=62) | (n=59) | |
systemic treatment side effects | 13,9 (14,2) | 15,4 (16,0) |
body image | 73,7 (28,6) | 73,0 (30,9) |
future perspective | 52,7 (29,9) | 54,2 (29,0) |
arm symptoms | 23,8 (22,6) | 24,9 (21,6) |
breast symptoms | 21,9 (18,6) | 19,9 (16,6) |
| Â | CR (n=8) | TT (n=13) |
upset by hair loss | 33,3 (35,6) | 35,9 (39,6) |
| Â | CR (n=56) | TT (n=54) |
sexual functioning | 22,3 (23,2 | 25,0 (23,3) |
| Â | CR (n=28) | TT (n=33) |
sexual enjoyment | 56,0 (28,8) | 55,6 (28,5) |